Abstracts Archive - Page 1132 of 2607 - ACR Meeting Abstracts

Abstract Number: 2882 • 2019 ACR/ARP Annual Meeting
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Vera Golder¹, Molla Huq ², Rangi Kandane-Rathnayake ³, Worawit Louthrenoo ⁴, Shue Fen Luo ⁵, Yeong-Jian Wu ⁵, Aisha Lateef ⁶, Sargunan Sockalingam ⁷, Sandra Navarra ⁸, Leonid Zamora ⁹, Laniyati Hamijoyo ¹⁰, Yasuhiro Katsumata ¹¹, Masayoshi Harigai ¹², Madelynn Chan ¹³, Sean O'Neill ¹⁴, Fiona Goldblatt ¹⁵, Chak Sing Lau ¹⁶, Zhanguo Li ¹⁷, Alberta Hoi ¹⁸, Mandana Nikpour ¹⁹ and Eric Morand ¹, ¹Monash University, Melbourne, Victoria, Australia, ²University of Melbourne, Melbourne, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University Hospital, Chiang Mai, Thailand, ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶National University Hospital, Singapore, Singapore, ⁷University of Malaya, Kuala Lumpur, Malaysia, ⁸University of Santo Tomas Hospital, Manila, Philippines, ⁹Santo Tomas Hospital, Manila, Philippines, ¹⁰Padjadjaran University, Bandung, Indonesia, ¹¹Tokyo Women's University, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴University of New South Wales, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁹St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) is a treatment endpoint for SLE that has been shown in prospective validation studies to be associated…
Abstract Number: 2883 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
April Barnado¹, Lee Wheless ¹, Leslie Crofford ² and Joshua Denny ¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria…
Abstract Number: 2884 • 2019 ACR/ARP Annual Meeting
Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years
Mitra Moazzami¹, Vibeke Strand ², Jiandong Su ³ and Zahi Touma ⁴, ¹George Washington University, Washington, DC, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Fatigue is very common in SLE patients. We aim to: 1) determine if different trajectories of fatigue associate with specific latent classes of disease…
Abstract Number: 2885 • 2019 ACR/ARP Annual Meeting
An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
Chiara Bellocchi ¹, Álvaro Fernández-Ochoa ², Gaia Montanelli ³, Barbara Vigone ³, Alessandro Santaniello ³, Rosa Quirantes-Piné ⁴, Isabel Borrás-Linares ⁴, Maria Gerosa ⁵, Carolina Artusi ⁶, Roberta Gualtierotti ⁶, Antonio Segura-Carrettero ⁴, Marta E. Alarcón-Riquelme ⁷ and Lorenzo Beretta³, ¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy, Milan, Italy, ². Department of Analytical Chemistry, University of Granada, Granada, Spain, Granda, Spain, ³Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, Milan, Italy, ⁴Department of Analytical Chemistry, University of Granada, Granada, Spain, Granada, Spain, ⁵Istituto Ortopedico Gaetano Pini, University of Milan, Milan, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Milan, Italy, ⁷Centro de Genómica e Investigaciones Oncológicas Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain
Background/Purpose: Gut microbiota may be relevant in the regulation of immune processes and in the development of systemic autoimmune diseases (SADs). A reduction of microbiota…
Abstract Number: 2886 • 2019 ACR/ARP Annual Meeting
Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
Emily Somers¹, Lu Wang ², W Joseph McCune ³, S Sam Lim ⁴, Cristina Drenkard ⁴, Elizabeth Ferucci ⁵, Maria Dall'Era ⁶, Caroline Gordon ⁷, Charles Helmick ⁸, Hilary Parton ⁹ and Peter Izmirly ¹⁰, ¹University of Michigan Schools of Medicine & Public Health, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴Emory University, Atlanta, GA, ⁵Alaska Native Tribal Health Consortium, Anchorage, AK, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁹New York City Department of Health & Mental Hygiene, Long Island City, NY, ¹⁰NYU School of Medicine, New York
Background/Purpose: The heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) and lack of a diagnostic test make SLE difficult for epidemiologists to study.…
Abstract Number: 2887 • 2019 ACR/ARP Annual Meeting
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Sonali Narain¹, Daniel Wallace ², Chaim Putterman ³, Cristina Arriens ⁴, Anca Askanase ⁵, Kenneth Kalunian ⁶, Christopher Collins ⁷, Amit Saxena ⁸, Elena Massarotti ⁹, Roberta Alexander ¹⁰, Claudia Ibarra ¹⁰, Tyler O'Malley ¹¹, John Conklin ¹⁰, Rosalind Ramsey-Goldman ¹², Joseph Ahearn ¹³, Susan Manzi ¹³, Arthur Weinstein ¹⁰ and Thierry Dervieux ¹⁰, ¹Northwell Health, Great Neck, Long Island, NY, ²Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ³Albert Einstein College of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Columbia University, New York, ⁶Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁷MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁸New York University School of Medicine, New York, NY, ⁹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ¹⁰Exagen, Vista, CA, ¹¹Exagen, Oceanside, CA, ¹²Northwestern University, Chicago, IL, ¹³Allegheny Health Network, Pittsburgh
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are stable forms of classical complement activation ex-vivo, with high sensitivity and specificity for systemic lupus erythematosus (SLE). We…
Abstract Number: 2888 • 2019 ACR/ARP Annual Meeting
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
Francine Castillo¹, Adrienne Strait ², Michael Evans ³, Julia Kay ⁴, Milena Gianfrancesco ⁵, Zara Izadi ⁶, Laura Trupin ¹, Mylien Hoang ⁷, James Shalaby ⁸, Gabriela Schmajuk ⁹ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF School of Medicine, San Francisco, CA, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, ⁶UCSF Division of Rheumatology, San Francisco, ⁷Touro University, San Francisco, ⁸Elimu Informatics, San Francisco, ⁹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and…
Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Natalie McCormick¹, Zachary Wallace ², Chio Yokose ³, April Jorge ³, Chana Sacks ⁴, John Hsu ⁵ and Hyon K. Choi ³, ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, ⁵Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…
Abstract Number: 2890 • 2019 ACR/ARP Annual Meeting
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo¹, George Tomlinson ², Edward Keystone ³, Michael Paterson ⁴, Nick Bansback ⁵ and Claire Bombardier ⁶, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, Canada, ⁵University of British Columbia, Vancouver, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are…
Abstract Number: 2891 • 2019 ACR/ARP Annual Meeting
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
James Sullivan¹, Jeffrey Katz ² and Elena Losina ³, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital/Harvard Medical School, Boston, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for…
Abstract Number: 2892 • 2019 ACR/ARP Annual Meeting
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Celine van de Laar¹, Martijn A.H. Oude Voshaar ², Carly Janssen ³, Matthijs Janssen ⁴, Maiwenn Al ⁵ and Mart A.F.J. van de Laar ⁶, ¹Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands, ²Transparency in Healthcare B.V. and Department of Psychology, Health & Technology, University of Twente, Hengelo, Netherlands, ³Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands, ⁵Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from…
Abstract Number: 2893 • 2019 ACR/ARP Annual Meeting
Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation
Genevieve Silva¹, James Sullivan ², Jeffrey Katz ³, Stephen Messier ⁴ and Elena Losina ⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital/Harvard Medical School, Boston, ⁴Wake Forest University, Winston Salem, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: The United States (US) knee osteoarthritis (OA) population has low levels of physical activity (PA), despite its well-defined health benefits. Interventions to promote PA…
Abstract Number: 2894 • 2019 ACR/ARP Annual Meeting
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
Evan Der ¹, Ting Zhang ², Chi Chiu Mok ³, Ramesh Saxena ⁴, Krishna R. Polu ⁵, Chandra Mohan ⁶ and Chaim Putterman⁷, ¹Albert Einstein College of Medicine, New York, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴University of Texas South Western, Dallas, TX, ⁵Equillium, San Diego, CA, ⁶University of Houston, Houston, ⁷Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in Systemic lupus erythematosus (SLE) patients. However, the pathogenesis of renal disease in…
Abstract Number: 2895 • 2019 ACR/ARP Annual Meeting
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Anne Troldborg¹, Anne Voss ², Søren Werner Karlsjov Hansen ³, Jens Christian Jensenius ⁴, Kristian Stengaard-Pedersen ⁵ and Steffen Thiel ⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Odense University Hospital, Department of Rheumatology, Odense, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Aarhus University, department of biomedicine, Aarhus, Denmark, ⁵Department of Rheumatology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark
Background/Purpose: Nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that develops in 30 to 50 percent of the patients. At the time of…
Abstract Number: 2896 • 2019 ACR/ARP Annual Meeting
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera¹, Alejandro Ibañez-Costa ¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Maria del Carmen Abalos-Aguilera ¹, Ivan Arias de la Rosa ⁴, Nuria Barbarroja ⁵, Mario Espinosa ⁶, Eduardo Collantes-Estevez ⁴, Justo Castaño ⁷, Raúl Luque ⁷ and Carlos Perez-Sanchez ⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶UGC de Nefrología. Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Maimónides Institute for Biomedical Research at Córdoba, Cordoba, Spain, ⁸Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].